Reshape Lifesciences Inc's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 6.32, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the first quarter 2026. Average receivable collection period, for the Reshape Lifesciences Inc in Mar 31 2026 quarter, has decreased to 58 days, compared to 71 days, in the Sep 30 2025 quarter.

If we take a look into Healthcare sector 365 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Mar 31 2026 from 1953 to 2204.

What is Receivable Turnover Ratio?
What is Reshape Lifesciences Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RSLS Receivables Turnover Ratio	(Mar 31 2026) I. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Receivable Change	-	-98.29 %	-43.92 %	-53.13 %	-40.51 %
Y / Y Revenue Change	-96.31 %	-98.49 %	-36.79 %	-42.75 %	-55.23 %
Receivable Turnover Ratio (TTM)	6.32	5.15	5.73	5.6	5.35
RSLS's Total Ranking	# 2204	# 1953	# 2322	# 2318	#
Accounts Receivable average collection period days	58	71	64	65	68
Seq. Receivable Change	-	-97.03 %	5.59 %	-25.63 %	-26.56 %
Seq. Revenue Change	-8.77 %	-97.21 %	11.59 %	30.02 %	-62.65 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 113
Healthcare Sector	# 366
Overall Market	# 2204

Receivable Turnover Ratio Statistics
High	Average	Low
1.13	0.38	0.01
(Dec 31 2024)		(Dec 31 2018)

RSLS Company Profile • Back to RSLS Efficiency Comparisons • Compare RSLS Receivables Turnover Ratio to its Competitors

Financial Statements
Reshape Lifesciences Inc's Accounts Receivable	$ 0 Millions	Visit RSLS's Balance sheet
Reshape Lifesciences Inc's Sales TTM	$ 2 Millions	Visit RSLS's Income Statement
Sources of RSLS's Revenues		Visit RSLS's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
RSLS's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
RSLS's Growth Rates	RSLS's Roa	RSLS's Inventory Turnover Ratio	RSLS's Dividend Comparisons
RSLS's Profitability Ratios	RSLS's Roi	RSLS's Asset Turnover Ratio	RSLS's Dividend Growth
RSLS's Valuation Ratios	RSLS's Roe	RSLS's Financial Strength Ratios	RSLS's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2026, within Healthcare Sector

Receivable Turnover Ratio

Revenues for 12 Months ending Mar 31 2026

Receivable at quarter ending Mar 31 2026

Date modified: 2026-08-30T14:56:47+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.